Further emphasizing targeted approaches, docetaxel and resveratrol were encapsulated in epidermal growth factor receptor-targeted lipid–polymer hybrid nanoparticles (EGF DTX/RSV LPNs) designed for the targeted treatment of non-small cell lung cancer (NSCLC). This evidence concerns the gene EGF and non-small cell lung carcinoma.